Oblenio Bio raised $62 million in an oversubscribed Series B led by Pfizer Ventures to advance a trispecific T-cell engager (TCE) for autoimmune disease into a first-in-human study. The financing underscores continued investor appetite for early, mechanism-driven immunology assets—particularly those designed to engage T cells through multimodal targeting. The company said the funds will move the TCE program through initial clinical readiness, marking the next step from development into human dosing. For Pfizer Ventures, the investment adds to its footprint in cell- and immune-engagement platforms with long-term commercialization potential. The deal also signals that autoimmune immunotherapy remains an active funding area as investors look for differentiated engagement biology rather than incremental modifications. In the near term, the key datapoints for the field will be safety and early pharmacodynamic evidence in first-in-human dosing.